Assessment of the Muscle Protein Fractional Synthesis Rate Induced by Repeated Administrations of GLPG0492 to Healthy Male Subjects and Assessment of the Safety, Tolerability and Pharmacokinetics of Repeated Administrations of GLPG0492 to Healthy Postmenopausal Women.

GLPG0492 is a selective androgen receptor modulator: the compound should help protect against (or help restore) muscle loss in case of immobilization (e.g. after orthopedic surgery) or due to aging (androgenic effect), but without anabolic effects (e.g. effect on testosterone). In the first part of the current study it will be tested whether GLPG0492 given orally to healthy male volunteers increases the protein synthesis in muscle, as measured by the uptake into the muscle of intravenously infused phenylalanine.
In the second part of the study, the effect of the compound on the "hormone household" in healthy, postmenopausal women will be assessed.

开始日期2012-01-01

申办/合作机构

Galapagos NV

NCT01397370

/ Completed临床1期

Double Blind, Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of GLPG0492 in Healthy Subjects

The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses (MAD) of GLPG0492 given to healthy subjects for 14 days compared to placebo, and to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0492 after multiple oral administrations.

开始日期2011-07-01

申办/合作机构

Galapagos NV

NCT01130818

/ Completed临床1期

Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of GLPG0492 in Healthy Subjects and Open Relative Bioavailability Study of Oral Solution Versus Solid Formulation, Fasted and Fed, in Elderly Subjects

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) oral dose of GLPG0492 compared to placebo in healthy subjects.
Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0492 after single oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined. Oral bioavailability (solution vs solid capsule fasting or fed) is evaluated in healthy elderly subjects.

开始日期2010-05-01

申办/合作机构

Galapagos NV

100 项与 GLPG-0492 相关的临床结果

登录后查看更多信息

100 项与 GLPG-0492 相关的转化医学

登录后查看更多信息

100 项与 GLPG-0492 相关的专利（医药）

登录后查看更多信息

144

项与 GLPG-0492 相关的文献（医药）

2025-11-01·JPGN reports

Drug‐induced liver injury associated with selective androgen receptor modulators in an adolescent patient

Article

作者: Brent Polk, D. ; Shayan, Katayoon ; Katibian, David J. ; Bauman, Laura E.

ABSTRACT:

Selective androgenic receptor modulators (SARMs) have similar properties to anabolic steroids but bind to androgen receptors in a tissue‐specific manner. Studies have investigated the benefits of SARMs in promoting bone and muscle growth while limiting the adverse effects of androgenic stimulation of other organs. However, an increase in the reported cases of hepatotoxicity in adults secondary to SARMs found in bodybuilding supplements has raised concerns about their safety. We report the first known adolescent case of SARMs‐associated liver injury with a primarily hepatocellular pattern of injury. Previous reports in adults had shown a primarily cholestatic pattern of injury. Our case highlights, the variations in the phenotypic and histologic patterns of injury based on the amount and type of SARMs. The purpose of this case report is to shed light on the potential spectrum of liver injury related to SARMs use and continue to raise awareness of the associated health risks.

2025-11-01·JOURNAL OF ANALYTICAL TOXICOLOGY

Exploring transdermal SARMs exposure: analysis of the elimination profiles and metabolism for doping control purposes

Article

作者: Thomas, Andreas ; Alhalabi, Hana ; Krombholz, Sophia ; Korsmeier, Linus ; Thevis, Mario

Abstract:

Transdermal drug delivery has been of particular interest to pharmaceutical research for decades, but is also becoming increasingly relevant in the field of sports drug testing. As shown in the past, the (unintentional) oral ingestion of trace amounts of prohibited selective androgen receptor modulators (SARMs), e.g. due to product contamination, can lead to an adverse analytical finding (AAF) in doping controls. Another site of exposure is presented by the skin, as it provides a large surface for drug penetration. However, the extent of diffusion through various layers of the skin and into the blood vessels depends, among other things, on the physicochemical and biological properties of a substance. The objective of this project was to simulate a transdermal contamination scenario and investigate the skin penetration and subsequent metabolism of microdoses of three commonly used SARMs: LGD-4033, RAD140, and S-23. For this purpose, an administration study was conducted, in which either 10 or 50 µg of the substances were applied to the lower forearm of 5 volunteers each. The collected urine samples were analyzed via LC–MS/MS following enzymatic hydrolysis and solid-phase extraction. This methodical approach is distinguished by its high sensitivity, enabling the detection of at least 5 pg/mL for LGD-4033 and S-23. After 10 µg administration, LGD-4033 and S-23 as well as associated metabolites were detected, while RAD140 was only detected in urine samples of one subject (n = 5). Following the application of 50 µg, RAD140 was detected in all subjects (n = 5) for up to 9 days, and additional metabolites of LGD-4033 and S-23 were identified. The long-term metabolite of LGD-4033 (M5b) was detected up to 12 days after the dermal administration of 10 µg, and up to 25 days after application of 50 µg, while S-23 was traceable for up to 16, respectively 24 days. It was demonstrated for all three SARMs that they penetrate the skin and may—even in trace amounts—produce AAFs when administered transdermally. Information on urinary concentrations and metabolism following transdermal administration of SARMs may assist in the interpretation of AAFs, particularly when dermal contamination or intentional doping via the skin is discussed.

2025-10-01·JOURNAL OF ANALYTICAL TOXICOLOGY

Drug transfer during intimate moments can produce an adverse analytical finding during a doping control: A case report with ligandrol

Article

作者: Kintz, Pascal ; Gheddar, Laurie

Abstract:

Selective androgen receptor modulators (SARMs) are a new class of substances that have similar properties to anabolic steroid agents, but with marked reduced androgenic properties. As SARMs have the potential to be misused for performance enhancement in sport due to their anabolic properties as well as their ability to stimulate androgen receptors in the muscle and the bone, they have been prohibited at-all-times by the World Anti-Doping Agency (WADA) since 2008 under section S1.2 of the List. Ligandrol is one of the more popular SARMs. A WADA-accredited laboratory identified bishydroxy-ligandrol in the urine of a female athlete, the major ligandrol metabolite at approximately 90 pg/mL (specimen A) and 200 pg/mL (specimen B). The athlete challenged this anti-doping rule violation and requested a hair test to document possible incidental exposure. About 7 weeks after urine collection, a hair specimen (brown in color and > 20 cm in length) was collected and segmented in 6 × 1 cm segments. Ligandrol was tested by liquid chromatography–tandem mass spectrometry after alkaline incubation and extraction. With a limit of quantitation at 1 pg/mg, no ligandrol was identified. It appears that the athlete was unaware her husband was taking the substance, which was confirmed by his hair test (ligandrol at 7 and 8 pg/mg in 2 × 2.5 cm segments). The Court of Arbitration for Sports accepted the athlete’s explanation that she had been exposed to ligandrol through the exchange of bodily fluids with her husband and lifted her provisional ban. This case demonstrates that drug transfer between two subjects is possible during intimate moments.

项与 GLPG-0492 相关的新闻（医药）

2026-02-24

·骨科先生Dr Yang

文献速递 | 肌少症综述：如何诊断与治疗（PMID：40098209）

点击蓝字关注我们这篇发表于《Knee Surgery & Related Research》2025 年的综述系统阐述了肌少症（Sarcopenia）的核心研究进展，明确其为与衰老相关、以肌肉量减少、肌力下降、身体机能降低为特征的进行性骨骼肌疾病，全球老年人群患病率最高可达50%；其成因涉及神经退行性变、营养不足、激素变化等多方面，发病机制与细胞凋亡、蛋白水解等相关，EWGSOP2019和AWGS2019分别制定了差异化诊断标准与流程，还有 CT/MRI、超声等新型诊断工具；预防以均衡饮食、足量蛋白摄入和规律运动为核心，管理则依靠抗阻运动、营养补充、多重用药减药三大核心手段，目前尚无获批治疗药物，SARMs、比马鲁单克隆抗体等处于研究阶段；肌少症与膝骨关节炎（KOA）密切相关，是其发病危险因素，还会显著降低全膝关节置换术（TKA）预后并增加术后并发症风险，临床需重视肌少症的个性化管理以改善膝关节相关疾病诊疗效果。一、肌少症的定义与鉴别 1、核心定义：1989 年由 Rosenberg 提出，源于希腊语 “肌肉贫乏”，现定义为与衰老相关的进行性骨骼肌疾病，以肌肉量减少、肌力下降为核心，可导致跌倒、机能衰退、衰弱甚至死亡；EWGSOP2019（欧洲老年肌少症2019年工作组）将低肌力作为核心特征，AWGS2019（亚洲肌肉减少症工作组 2019 共识）定义为年龄相关肌肉量丢失合并低肌力 / 低身体机能，亚洲老年年龄界限定为 60 或 65 岁。 2、鉴别诊断 o衰弱：多系统损伤，应激下难以维持内环境稳态，符合不明体重下降、疲劳等 5 项中 3 项即可诊断； o恶病质：由基础疾病（癌症、艾滋病等）的炎症和代谢紊乱驱动，属于肌少症的病理性亚类。二、流行病学特征肌少症患病率随年龄增长显著升高，且存在地域、性别差异，关键数字如下： ·欧洲 40-79 岁成人患病率1.6%，英国≥85 岁成人3.6%； ·全球≥50 岁社区人群1%-29%，>80 岁人群升至11%-50%； ·亚洲人群整体5.5%-25.7%，男性（5.1%-21.0%）高于女性（4.1%-16.3%）。三、成因与发病机制（一）主要成因肌少症的发生是多因素共同作用的结果，核心因素包括： 1、神经退行性变：运动皮层、脊髓、外周神经元及神经肌肉接头退变，运动神经元数量减少，肌纤维数量下降； 2、营养不足：≥70 岁老人近 40% 蛋白质摄入未达 0.8g/kg 的推荐量，韩国研究显示肌少症患者蛋白达标率显著更低；维生素 D 缺乏可直接导致肌肉量和肌力丢失，是独立危险因素； 3、激素变化：50 岁左右男女出现激素衰退，睾酮、雌激素、生长激素（GH）、胰岛素样生长因子 1（IGF-1）下降，影响肌肉合成与再生； 4、促炎因子升高：TNF-α、IL-6 等促炎因子水平上升，促进肌肉蛋白分解并触发凋亡，IL-6 还会引发肌少性肥胖； 5、卫星细胞激活减少：骨骼肌卫星细胞数量下降、增殖能力减弱，肌肉损伤后再生能力降低。（二）核心发病机制 1、细胞凋亡：特有的肌核凋亡，肌细胞核浓缩、数量减少，无完整细胞死亡； 2、蛋白水解：自噬、钙蛋白酶激活、泛素 - 蛋白酶体系统为三大核心蛋白降解机制，在肌肉萎缩中均被激活； 3、信号通路抑制：Akt/mTOR/p70S6K 通路（促进肌肉生长）在老年 Ⅱ 型肌纤维中选择性下调，肌抑素会抑制该通路并阻碍肌肉生长。四、诊断标准与工具目前国际主流诊断标准为 EWGSOP2019 和 AWGS2019，二者均以肌肉量、肌力、身体机能为核心指标，GLIS2024（全球肌少症领袖倡议）推动了全球共识的建立，核心内容如下：（一）主流诊断标准（关键数值见表 1） 1、EWGSOP2019 四步法：先通过 SARC-F 问卷（肌少症筛查量表）找病例，再评估肌力，确认肌肉量 / 质量后分级身体机能，重度需满足三项指标； 2、AWGS2019 特色：提出可能肌少症概念（低肌力伴 / 不伴低机能），适用于基层筛查；病例筛查可采用小腿围（男< 34cm，女 < 33cm）、SARC-F（≥4分）、SARC-CalF（≥11 分）。（二）新型诊断工具 1、影像学：CT/MRI可测量肌肉量、评估肌肉内脂肪浸润，超声便携且成本低，可检测肌肉厚度和脂肪浸润； 2、生化试验：肌酸稀释试验通过氘标记肌酸估算全身肌肉量，与 MRI 结果高度相关； 3、量表：SarQoL量表评估肌少症对患者生活质量的影响，涵盖生理、心理、社会维度。 SarQoL 量表（Sarcopenia Quality of Life questionnaire）是全球首个针对肌少症的特异性健康相关生活质量评估工具，专为测量肌少症对患者生理、心理及社会功能的影响而设计，已在多国验证并广泛应用于临床研究与实践。（三）全球共识（GLIS2024）通过德尔菲法达成共识，明确肌少症是潜在可逆的全身性骨骼肌疾病，核心成分为肌肉量、肌力、肌肉比肌力，身体机能下降为疾病结局而非核心成分；其会增加跌倒、骨折、住院、死亡等多种不良结局风险。五、预防与管理目前肌少症无根治手段，预防以健康生活方式为核心，管理以抗阻运动、营养补充、多重用药减药为三大核心手段，具体如下：（一）预防策略 1、核心：均衡饮食、足量蛋白质摄入、规律运动，高危人群需制定个性化运动和饮食方案； 2、饮食：推荐植物蛋白、果蔬、坚果、植物油脂替代肉类和加工食品，补充维生素D； 3、特殊人群：抑郁是肌少症危险因素（HR=1.34），抑郁人群保持健康生活方式可降低 18% 患病风险。（二）核心管理手段 1、抗阻运动：最有效手段，持续3 个月及以上可显著改善肌少症相关指标；联合有氧 / 平衡运动可改善生活质量、肌力和身体机能，简易椅上站立运动也可降低卒中后肌少症患病率，提升肌肉指数和握力； 2、营养补充 o 蛋白质：老年肌少症患者推荐1-1.5g/kg/ 天，优先选择亮氨酸丰富的乳清蛋白； o 其他：补充维生素D、肌酸、ω-3 脂肪酸、益生菌，充足饮水可降低患病风险； o 联合效果：乳清蛋白+ 亮氨酸 + 维生素 D 补充，单独使用可增加肌肉量，联合运动可同时改善肌力和身体机能； 3、多重用药减药：肌少症与多重用药显著相关（OR=1.65），减药可改善卒中后肌少症患者的机能评分，提高居家出院概率（OR=1.393）。六、未来治疗方向 1、药物研发：目前尚无FDA 获批的肌少症治疗药物，处于研究阶段的药物有： o SARMs（选择性雄激素受体调节剂）：可增加女性肌少症患者瘦体重，但未改善肌力和身体机能； o 比马鲁单克隆抗体：抑制肌抑素和激活素 A，Ⅱ 期研究显示可提升握力和大腿肌肉量，但 Ⅲ 期研究未证实其对身体机能的改善作用； 2、个性化营养：基于性别、肠道菌群、生活方式等个体差异制定饮食方案，初步研究显示可改善老年人群 400m 步行时间和伸膝肌力，但仍需大样本研究验证。七、肌少症与膝关节疾病的关联肌少症与膝关节相关疾病密切相关，是膝骨关节炎的危险因素，还会显著影响全膝关节置换术（TKA）的预后，核心结论如下： 1、与膝骨关节炎（KOA） o 共病率高：KOA患者肌少症患病率45.2%，远高于非KOA 人群的31.2%，KOA患者患肌少症的风险是普通人群的2.07 倍； o 因果关系：孟德尔随机化研究显示，四肢瘦体重是 KOA 的因果危险因素，肌力无直接因果作用；KOA 对肌少症无显著反向因果影响； o 争议：部分研究认为肌少性肥胖而非肌少症本身是 KOA 的危险因素，需单独分析两类人群。 2、与全膝关节置换术（TKA） o 患病率：TKA患者肌少症患病率20.1%； o 预后影响：肌少症患者术后膝关节功能评分显著降低，术后并发症发生率（14.1%）远高于健康人群（4.1%）； o并发症：肌少症会增加 TKA 术后输血、肺炎、尿路感染、假体骨折 / 脱位 / 松动、假体周围感染等多种并发症风险。八、研究结论 1、肌少症是老年人群的重要病理性状态，随衰老发病率升高，但可通过健康生活方式有效预防； 2、目前无获批治疗药物，抗阻运动 + 合理营养补充是肌少症管理的核心手段，因病因多样，需制定个性化诊疗方案； 3、肌少症与膝骨关节炎密切相关，是其发病危险因素，同时会降低TKA 预后并增加术后并发症，临床管理膝关节疾病时需重视肌少症的筛查与干预。【参考文献】 Chung JY, Kim SG, Kim SH, Park CH. Sarcopenia: how to determine and manage. Knee Surg Relat Res. 2025 Mar 17;37(1):12. doi: 10.1186/s43019-025-00265-6. PMID: 40098209; PMCID: PMC11912661. 喜欢本文请点赞分享一下吧！

临床研究临床结果

2026-01-27

·肿瘤防治在线

恶病质的发展史与有效药物：从认知模糊到多靶点干预

点击蓝字关注我们恶病质的医学认知历经数百年演进，从最初的“不明消耗”逐步明确为“多因素介导的代谢紊乱综合征”，其治疗药物也从单一改善食欲，发展为涵盖抑制分解、促进合成的多靶点方案，具体如下：一、恶病质的发展史：从现象描述到机制明晰恶病质的认知历程可分为早期现象观察、中期病因关联、现代机制研究三个阶段，核心是逐步明确其与基础疾病的关联及病理机制： 1. 早期现象观察阶段（19世纪前）：认知模糊，仅描述症状 “恶病质”（Cachexia）一词源于希腊语“kakos”（恶劣）与“hexis”（状态），最早可追溯至公元前400年希波克拉底时代，当时仅用于描述“身体极度消瘦、虚弱”的终末期状态，未关联具体疾病，也无明确诊断标准。 19世纪前，医学水平有限，医生普遍认为恶病质是“疾病终末期的自然表现”，如肺结核、恶性肿瘤患者晚期出现的消瘦，被视为“机体衰竭的必然结果”，无针对性干预手段，仅通过补充肉汤、谷物等基础营养缓解症状，效果极差。 2. 中期病因关联阶段（20世纪-21世纪初）：明确与基础疾病的绑定 20世纪随着肿瘤学、慢性病学的发展，医生逐渐发现恶病质并非“独立状态”，而是与特定疾病紧密相关： - 1920年代：研究发现**恶性肿瘤**是恶病质最主要诱因，约80%晚期肿瘤患者会出现恶病质，且消瘦程度与肿瘤分期、预后直接相关（如胰腺癌、肺癌患者恶病质发生率显著高于乳腺癌）； - 1950年代：进一步发现慢性肾病、慢性阻塞性肺疾病（COPD）、心力衰竭等非肿瘤性疾病，也会引发类似的消耗症状，明确恶病质的核心是“基础疾病导致的代谢失衡”； - 2006年：国际恶病质共识首次给出明确定义——“由疾病引发的、以持续骨骼肌流失（伴或不伴脂肪流失）为核心，不能通过常规营养支持逆转的消耗综合征”，标志着恶病质从“症状描述”进入“标准化医学概念”阶段。 3. 现代机制研究阶段（21世纪以来）：揭示多因子介导的病理过程随着分子生物学发展，恶病质的机制研究逐步深入，明确其本质是“促分解代谢因子”与“抗分解代谢因子”失衡： - 核心机制：肿瘤细胞或炎症细胞分泌**肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、干扰素-γ（IFN-γ）** 等“促消耗因子”，加速肌肉蛋白分解、抑制蛋白合成，同时干扰脂肪代谢，导致肌肉-脂肪双流失； - 关键发现：2010年后发现“肌肉生长抑制素”（Myostatin）在恶病质中起关键作用——该因子过度表达会抑制肌肉干细胞增殖，导致肌肉无法修复，为药物研发提供了新靶点。二、恶病质的有效药物：从改善症状到靶向干预目前恶病质药物尚无“根治性方案”，核心是针对“食欲减退、肌肉分解、炎症反应”三大靶点，缓解症状、延缓进展，主要分为以下四类： 1. 改善食欲与体重类药物：缓解“摄入不足” 这类药物是恶病质治疗的基础，通过刺激食欲、增加食物摄入，间接减少肌肉流失，临床应用最广泛： - 甲地孕酮：人工合成孕激素，通过作用于中枢神经系统食欲调节中枢，促进食欲、增加体重，对肿瘤相关恶病质的食欲改善有效率达60%-70%。需注意副作用——可能增加血栓风险（尤其是有血栓病史者）、升高血糖，需定期监测凝血功能与血糖； - 奥氮平：抗精神病药物，兼具改善食欲与缓解恶心的双重作用，适合因恶心、焦虑导致食欲差的恶病质患者（如化疗相关恶病质），副作用主要为嗜睡，需避免与镇静药物联用。 2. 抑制肌肉分解类药物：减少“消耗过多” 针对恶病质的核心——肌肉流失，通过抑制分解代谢通路，保护肌肉量： - 依那西普：肿瘤坏死因子（TNF-α）拮抗剂，可阻断TNF-α介导的肌肉分解通路，尤其适合炎症反应显著的恶病质患者（如类风湿关节炎合并恶病质）。但因可能抑制免疫力，肿瘤患者需谨慎使用，避免加重感染风险； - 鱼油制剂（ω-3脂肪酸）：通过抑制炎症因子（如IL-6）释放，减轻炎症介导的肌肉分解，同时可改善食欲，适合轻中度恶病质患者，副作用少（仅少数人出现胃肠道不适），常作为辅助治疗。 3. 促进肌肉合成类药物：主动“修复肌肉” 通过激活肌肉 - 左卡尼汀：促进脂肪酸氧化，为肌肉合成提供能量，同时减少肌肉乳酸堆积，缓解乏力，可用于各类恶病质患者，尤其适合合并肌肉酸痛者，无明显副作用； - 选择性雄激素受体调节剂（SARMs，如奥昔布宁）：可模拟雄激素的肌肉合成作用，且无传统雄激素的前列腺刺激副作用，目前在肿瘤恶病质中的临床试验显示可增加肌肉量，但尚未广泛获批，仅用于难治性病例。 4. 对症支持类药物：缓解伴随症状恶病质常合并疼痛、恶心、贫血等症状，需同步对症治疗，间接改善营养状态： - 镇痛药：如非甾体抗炎药（布洛芬）、弱阿片类药物（羟考酮），缓解肌肉酸痛、肿瘤相关疼痛，避免因疼痛影响进食与活动； - 止吐药：如昂丹司琼、帕洛诺司琼，缓解化疗或疾病本身导致的恶心呕吐，保证营养摄入； - 抗贫血药：如铁剂、促红细胞生成素，纠正恶病质相关贫血，改善乏力症状，提升活动能力。总结：药物需结合“病因控制”才有效【声明】本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被确切地视为诊疗建议。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。本文来自【天津市肿瘤医院苏雨栋教授】

2025-09-23

·EINPresswire

Agebox iKids Growth Night Formula may be harmful due to hidden ingredient

[9-23-2025] The Food and Drug Administration is advising consumers not to purchase or use Agebox iKids Growth Night Formula, a product promoted and sold to stimulate growth and promote health in children ages five and older. Agebox iKids Growth Night Formula is sold on various websites, including agebox.com and possibly in some retail stores. FDA laboratory analysis confirmed that Agebox iKids Growth Night Formula contains ibutamoren not listed on the product label. Ibutamoren (also known as MK-677) is an active ingredient not approved by FDA, and therefore its safety and efficacy have not been established. Ibutamoren is a growth hormone secretagogue that stimulates the release of growth hormone. Use of ibutamoren may cause serious side effects including increased appetite, water retention, fatigue, muscle pain, potential alterations in glucose metabolism and insulin sensitivity, and even may increase the potential for congestive heart failure in certain individuals. Long-term effects of ibutamoren use are unknown and may pose additional health risks. This ingredient may also interact with medications and products, like selective androgen receptor modulators (SARMs), a consumer may be taking in potentially harmful ways Health care professionals and consumers should report adverse events or side effects related to the use of this product to FDA's MedWatch Safety Information and Adverse Event Reporting Program: This notification is to inform the public of products potentially marketed as dietary supplements or conventional foods with hidden drug ingredients and chemicals. These products are typically promoted for sexual enhancement, weight loss, pain relief and body building and are often represented as being all natural. Consumers should exercise caution before purchasing these products. FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. For more information: Content current as of: 09/23/2025 Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 项与 GLPG-0492 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12461

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
杜氏肌营养不良症	临床1期	美国	Akashi Therapeutics Inc	2022-01-30
肌肉减少症	临床1期	比利时	Galapagos NV	2012-01-01
肌营养不良	药物发现	比利时	Akashi Therapeutics Inc	-